摘要
Objective:The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer(NSCLC)and to analyze the relationship between serum levels of CA19-9 and metastasis.Methods:Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively.The relationship between serum levels of CA19-9 and sites of metastasis were analyzed.Results:Of the 1200 patients,528 were stage IV and the positive rate of CA19-9 was 32%(169 cases)and 288 stage III,positive rate 20%(58 cases);144 stage II,positive rate 12%(17 cases);240 stage I,positive rate 3%(7 cases).There were statistical differences from stage I to stage IV(P<0.01).The total positive rate in the 1200 cases was 21%.Furthermore,of the 528 stage IV cases,350 had bone metastasis and the positive rate of CA19-9 was 43%(150 cases)in bone metastatic cases.In turn,in CA19-9 positive patients(169 cases)of stage IV, the positive rate of bone metastasis was 89%(150/169).There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma(P>0.05).Conclusion:Positive rate of CA19-9 increases accordingly from stage I to stage IV.The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC,especially for bone metastasis in stage IV diseases.
Objective： The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer （NSCLC） and to analyze the relationship between serum levels of CA19-9 and metastasis. Methods： Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively. The relationship between serum levels of CA19-9 and sites of metastasis were analyzed. Results： Of the 1200 patients, 528 were stage IV and the posi- tive rate of CA19-9 was 32% （169 cases） and 288 stage III, positive rate 20% （58 cases）; 144 stage II, positive rate 12% （17 cases）; 240 stage I, positive rate 3% （7 cases）. There were statistical differences from stage I to stage IV （P 〈 0.01）. The total positive rate in the 1200 cases was 21%. Furthermore, of the 528 stage IV cases, 350 had bone metastasis and the positive rate of CA19-9 was 43% （150 cases） in bone metastatic cases. In turn, in CA19-9 positive patients （169 cases） of stage IV, the positive rate of bone metastasis was 89% （150/169）. There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma （P 〉 0.05）. Conclusion： Positive rate of CA19-9 increases accordingly from stage I to stage IV. The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC, especially for bone metastasis in stage IV diseases.
